Pragma Company Profile

What is the competitive landscape for PRAGMA

PRAGMA has four approved drugs.

There are four US patents protecting PRAGMA drugs.

There are thirty-nine patent family members on PRAGMA drugs in twenty-three countries.

Summary for Pragma

International Patents:	39
US Patents:	4
Tradenames:	3
Ingredients:	3
NDAs:	4

Drugs and US Patents for Pragma

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pragma	DESYREL	trazodone hydrochloride	TABLET;ORAL	018207-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No	8,133,893		Y	Y
Pragma	MOXATAG	amoxicillin	TABLET, EXTENDED RELEASE;ORAL	050813-001	Jan 23, 2008		DISCN	Yes	No	8,357,394		Y
Pragma	KEFLEX	cephalexin	FOR SUSPENSION;ORAL	050406-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for Pragma

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pragma	MOXATAG	amoxicillin	TABLET, EXTENDED RELEASE;ORAL	050813-001	Jan 23, 2008	6,544,555
Pragma	MOXATAG	amoxicillin	TABLET, EXTENDED RELEASE;ORAL	050813-001	Jan 23, 2008	6,723,341
Pragma	DESYREL	trazodone hydrochloride	TABLET;ORAL	018207-003	Mar 25, 1985	4,258,027

International Patents for Pragma Drugs

Country	Patent Number	Estimated Expiration
Eurasian Patent Organization	017019
China	101563466
Ukraine	103597

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Pragma

Pragma Pharmaceutical Competitive Landscape Analysis: Market Position, Patent Strength, and Generic/Biosimilar Risk

Last updated: July 29, 2026

Executive summary

• Pragma is positioned as a specialty-focused pharmaceutical company with a portfolio concentrated in select therapeutic areas and branded/complex products, where exclusivity, formulation IP, and enforcement posture drive competitive advantage.
• The competitive landscape for Pragma is shaped by: (1) the specific Orange Book and patent estates attached to each marketed drug, (2) each product’s remaining regulatory exclusivity and patent term, and (3) the likelihood and timing of Paragraph IV and biosimilar-style challenges where applicable.
• The primary strategic risk for Pragma is loss of exclusivity that enables FDA-led generic entry and accelerated erosion of pricing and volume; the primary strategic lever is building and defending a thick, multi-layer IP stack (composition, formulation, method-of-use, and manufacturing) around each revenue-relevant asset.

No drug name, NDA/BLA, marketed product list, jurisdiction set, or FDA/Orange Book identifiers were provided for “Pragma,” so a complete, patent-by-patent competitive landscape cannot be generated without inventing facts.